First Manhattan CO. LLC. Sells 4,990 Shares of Sanofi (NASDAQ:SNY)

First Manhattan CO. LLC. lowered its holdings in Sanofi (NASDAQ:SNY) by 3.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 132,904 shares of the company’s stock after selling 4,990 shares during the quarter. First Manhattan CO. LLC.’s holdings in Sanofi were worth $6,410,000 as of its most recent filing with the SEC.

Other large investors also recently made changes to their positions in the company. Abel Hall LLC raised its position in shares of Sanofi by 1.8% during the fourth quarter. Abel Hall LLC now owns 10,990 shares of the company’s stock worth $530,000 after acquiring an additional 194 shares during the last quarter. Providence Capital Advisors LLC lifted its position in Sanofi by 0.4% during the 4th quarter. Providence Capital Advisors LLC now owns 55,001 shares of the company’s stock valued at $2,653,000 after purchasing an additional 201 shares during the period. Keudell Morrison Wealth Management boosted its stake in shares of Sanofi by 1.7% in the 4th quarter. Keudell Morrison Wealth Management now owns 12,928 shares of the company’s stock valued at $624,000 after purchasing an additional 217 shares during the last quarter. Bailard Inc. raised its stake in shares of Sanofi by 1.4% during the fourth quarter. Bailard Inc. now owns 16,359 shares of the company’s stock worth $789,000 after buying an additional 220 shares during the last quarter. Finally, Bessemer Group Inc. lifted its holdings in Sanofi by 59.8% in the fourth quarter. Bessemer Group Inc. now owns 647 shares of the company’s stock valued at $32,000 after buying an additional 242 shares during the period. Institutional investors own 14.04% of the company’s stock.

Sanofi Stock Down 4.1 %

Sanofi stock opened at $49.98 on Friday. The stock has a market capitalization of $126.26 billion, a PE ratio of 20.07, a price-to-earnings-growth ratio of 1.01 and a beta of 0.55. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. Sanofi has a twelve month low of $45.80 and a twelve month high of $60.12. The company has a 50 day moving average of $54.22 and a 200-day moving average of $52.00.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Thursday, April 24th. The company reported $0.94 earnings per share for the quarter, topping the consensus estimate of $0.90 by $0.04. The company had revenue of $10.41 billion during the quarter, compared to analysts’ expectations of $9.79 billion. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. The business’s quarterly revenue was down 11.0% on a year-over-year basis. During the same period last year, the business earned $1.78 EPS. On average, equities research analysts anticipate that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Increases Dividend

The firm also recently declared an annual dividend, which will be paid on Thursday, June 12th. Shareholders of record on Friday, May 9th will be given a dividend of $2.0369 per share. This represents a yield of 3.1%. The ex-dividend date is Friday, May 9th. This is an increase from Sanofi’s previous annual dividend of $1.48. Sanofi’s payout ratio is 57.14%.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on SNY. The Goldman Sachs Group assumed coverage on Sanofi in a research note on Friday, March 21st. They issued a “neutral” rating and a $65.00 price target on the stock. Hsbc Global Res raised Sanofi to a “strong-buy” rating in a research note on Monday, April 28th. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Finally, BNP Paribas started coverage on shares of Sanofi in a report on Tuesday, April 15th. They issued an “outperform” rating and a $65.00 price target for the company. Three equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $63.33.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.